Human plasma metabolic profiles of benzydamine, a flavin-containing monooxygenase probe substrate, simulated with pharmacokinetic data from control and humanized-liver mice

References

• Amidon GL, Sinko PJ, Fleisher D. (1988). Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm Res 5:651–4
   PubMed Web of Science ®Google Scholar
• Baldock GA, Brodie RR, Chasseaud LF, Taylor T. (1990). Determination of benzydamine and its N-oxide in biological fluids by high-performance liquid chromatography. J Chromatogr 529:113–23
   PubMed Web of Science ®Google Scholar
• Baldock GA, Brodie RR, Chasseaud LF, et al. (1991). Pharmacokinetics of benzydamine after intravenous, oral, and topical doses to human subjects. Biopharm Drug Dispos 12:481–92
   PubMed Web of Science ®Google Scholar
• Berry LM, Li C, Zhao Z. (2011). Species differences in distribution and prediction of human V(ss) from preclinical data. Drug Metab Dispos 39:2103–16
   PubMed Web of Science ®Google Scholar
• Catanese B, Grasso A, Silverstrini B. (1966). Studies on the absorption and elimination of benzydamine in the mouse, rat, dog, and man. Arzneimittelforschung 16:1354–7
   PubMed Web of Science ®Google Scholar
• Fisher MB, Yoon K, Vaughn ML, et al. (2002). Flavin-containing monooxygenase activity in hepatocytes and microsomes: in vitro characterization and in vivo scaling of benzydamine clearance. Drug Metab Dispos 30:1087–93
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ, Fang ZZ, Ma X. (2015). Transgenic mice and metabolomics for study of hepatic xenobiotic metabolism and toxicity. Expert Opin Drug Metab Toxicol 11:869–81
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (2008). Cytochrome P450 and chemical toxicology. Chem Res Toxicol 21:70–83
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Kawai K, Mitsui T, et al. (2011). The reconstituted 'humanized-liver' in TK-NOG mice is mature and functional. Biochem Biophys Res Commun 405:405–10
   PubMed Web of Science ®Google Scholar
• Jamei M, Dickinson GL, Rostami-Hodjegan A. (2009). A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of ‘bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet 24:53–75
   PubMed Web of Science ®Google Scholar
• Kamimura H, Ito S, Nozawa K, et al. (2015). Formation of the accumulative human metabolite and human-specific glutathione conjugate of diclofenac in TK-NOG chimeric mice with humanized-livers. Drug Metab Dispos 43:309–16
   PubMed Web of Science ®Google Scholar
• Kamimura H, Ito S, Chijiwa H, et al. (2016) Simulation of human plasma concentration-time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi-physiological pharmacokinetic modeling. Xenobiotica. [Epub ahead of print]. doi: 10.1080/00498254.2016.1199063
   Web of Science ®Google Scholar
• Kazuki Y, Akita M, Kobayashi K, et al. (2016). Thalidomide-induced limb abnormalities in a humanized CYP3A mouse model. Sci Rep 6:21419
   PubMed Web of Science ®Google Scholar
• Miyamoto M, Iwasaki S, Chisaki I, et al. (2016) Comparison of predictability for human pharmacokinetics parameters among monkeys, rats, and chimeric mice with humanised liver. Xenobiotica. [Epub ahead of print]. doi: 10.1080/00498254.2016.1265160
   PubMed Web of Science ®Google Scholar
• Nishiyama S, Suemizu H, Shibata N, et al. (2015). Simulation of human plasma concentrations of thalidomide and primary 5-hydroxylated metabolites explored with pharmacokinetic data in humanized TK-NOG mice. Chem Res Toxicol 28:2088–90
   PubMed Web of Science ®Google Scholar
• Schoenwald RD, Kumakura T, Catanese B. (1987). Pharmacokinetics of benzydamine. Int J Tissue React 9:93–7
   PubMedGoogle Scholar
• Shida S, Utoh M, Murayama N, et al. (2015). Human plasma concentrations of cytochrome P450 probes extrapolated from pharmacokinetics in cynomolgus monkeys using physiologically based pharmacokinetic modeling. Xenobiotica 45:881–6
   PubMed Web of Science ®Google Scholar
• Shida S, Yamazaki H. (2016). Human plasma concentrations of five cytochrome P450 probes extrapolated from pharmacokinetics in dogs and minipigs using physiologically based pharmacokinetic modeling. Xenobiotica 46:759–64
   PubMed Web of Science ®Google Scholar
• Shimizu M, Shiraishi A, Sato A, et al. (2015). Potential for drug interactions mediated by polymorphic flavin-containing monooxygenase 3 in human livers. Drug Metab Pharmacokinet 30:70–4
   PubMed Web of Science ®Google Scholar
• Shimizu M, Suemizu H, Mitsui M, et al. (2016). Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice. Xenobiotica. [Epub ahead of print]. doi: 10.1080/00498254.2016.1247218
   Web of Science ®Google Scholar
• Stormer E, Roots I, Brockmoller J. (2000). Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity. Br J Clin Pharmacol 50:553–61
   PubMed Web of Science ®Google Scholar
• Suemizu H, Hasegawa M, Kawai K, et al. (2008). Establishment of a humanized model of liver using NOD/Shi-scid IL2Rgnull mice. Biochem Biophys Res Commun 377:248–52
   PubMed Web of Science ®Google Scholar
• Taniguchi-Takizawa T, Shimizu M, Kume T, Yamazaki H. (2015). Benzydamine N-oxygenation as an index for flavin-containing monooxygenase activity and benzydamine N-demethylation by cytochrome P450 enzymes in liver microsomes from rats, dogs, monkeys, and humans. Drug Metab Pharmacokinet 30:64–9
   PubMed Web of Science ®Google Scholar
• Tateno C, Yoshizane Y, Saito N, et al. (2004). Near completely humanized-liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165:901–12
   PubMed Web of Science ®Google Scholar
• Tsukada A, Suemizu H, Murayama N, et al. (2013). Plasma concentrations of melengestrol acetate in humans extrapolated from the pharmacokinetics established in in vivo experiments with rats and chimeric mice with humanized-liver and physiologically based pharmacokinetic modeling. Regul Toxicol Pharmacol 65:316–24
   PubMed Web of Science ®Google Scholar
• Utoh M, Suemizu H, Mitsui M, et al. (2016). Human plasma concentrations of cytochrome P450 probe cocktails extrapolated from pharmacokinetics in mice transplanted with human hepatocytes and from pharmacokinetics in common marmosets using physiologically based pharmacokinetic modeling. Xenobiotica 46:1049–55
   PubMed Web of Science ®Google Scholar
• Yamazaki M, Shimizu M, Uno Y, Yamazaki H. (2014). Drug oxygenation activities mediated by liver microsomal flavin-containing monooxygenases 1 and 3 in humans, monkeys, rats, and minipigs. Biochem Pharmacol 90:159–65
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Suemizu H, Kazuki Y, et al. (2016a). Assessment of protein binding of 5-hydroxythalidomide bioactivated in humanized mice with human P450 3A-chromosome or hepatocytes by two-dimensional electrophoresis/accelerator mass spectrometry. Chem Res Toxicol 29:1279–81
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Suemizu H, Mitsui M, et al. (2016b). Combining chimeric mice with humanized-liver, mass spectrometry, and physiologically-based pharmacokinetic modeling in toxicology. Chem Res Toxicol 29:1903–11
   PubMed Web of Science ®Google Scholar
• Yeung CK, Lang DH, Thummel KE, Rettie AE. (2000). Immunoquantitation of FMO1 in human liver, kidney, and intestine. Drug Metab Dispos 28:1107–11
   PubMed Web of Science ®Google Scholar